Edoxaban
Evidence-based neurology checklist on edoxaban: Pharmacology Edoxaban is a factor Xa inhibitor Dose Risk factors for bleeding Treatment of bleeding
Pharmacology
- Edoxaban is a factor Xa inhibitor
Dose
Risk factors for bleeding
Treatment of bleeding
References
- Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43:1511-1517.
- Kreuzer J. Update on anti-coagulation in atrial fibrillation. Q J Med 2011; 104:747-760.
- Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Rev Cardiovasc Ther 2019; 17:319-330.
- Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020 (Online ahead of print).
- Mikami T, Hirabayashi K, Okawa K, et al. Laboratory test predictors for major bleeding in elderly (≥80 years) patients with nonvalvular atrial fibrillation treated with edoxaban 15 mg: sub-analysis of the ELDERCARE-AF Trial. J Am Heart Assoc 2022; 11:e024970.
- And 3 more. Subscribe to see the full list
